JOHN WADDINGTON: Curriculum Vitae
contact details

Professor of Neuroscience
Molecular & Cellular Therapeutics, RCSI

123 St Stephens Green, Dublin 2
jwadding@rcsi.ie
Telephone: 01 4022129
Mobile:
Fax: 01 4022453

Department Secretary: Anne Grady
Email: agrady@rcsi.ie
Telephone: 01 402 2420

education

1991: DSc, University of London. Neuroscience

1981: PhD, University of London. Psychopharmacology

1978: MA, University of Cambridge. Natural Sciences

1975: MSc, University of Bradford. Experimental Pharmacology

1974: BA (Hons), Class II (i), University of Cambridge. Natural Sciences

appointments

2004 to 2015: Co-Head, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1999 to date: Professor of Neuroscience, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1991 to 1998: Associate Professor of Neuroscience, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1988 to 1991: Reader in Neuroscience, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1985 to 1988: Senior Lecturer, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1981 to 1984: Lecturer, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland

1978 to 1981: Scientific Staff, Division of Psychiatry, MRC Clinical Research Centre, Northwick Park Hospital, Harrow, UK

1974 to 1978: Medical Research Council Scholar, Division of Psychiatry, MRC Clinical Research Centre, Harrow, UK

1974 to 1978: Demonstrator in Pharmacology, School of Pharmacy, University of London, UK

1974 to 1975: Medical Research Council Student and Demonstrator in Physiology, University of Bradford, UK

summary of research career to date

Following undergraduate and postgraduate studies in neuroscience and a period on the scientific staff of the UK Medical Research Council, my academic career in RCSI now involves directing a multidisciplinary research group that enjoys a distinguished international reputation in both preclinical and clinical neuroscience. Our primary focus is on psychotic illness [schizophrenia and bipolar disorder] and the application of mutant models to understand the developmental pathobiology of psychosis and antipsychotic drug action.

research interests

Epidemiology, pathobiology and treatment of psychotic illness schizophrenia and bipolar disorder; knockout and transgenic models involving genes associated with risk for and/or pathobiology of psychosis; mechanisms of action of antipsychotic drugs; functional roles of dopamine receptor subtypes; 3D surface imaging and geometric morphometrics of craniofacial dysmorphology as an index of brain dysmorphogenesis.

research areas

Neuroscience, Neuroendocrinology, Neurological diseases, Psychiatric diseases, Psychopharmacology

Memberships

Member, Ethics (Research) Committee, St Patrick’s Hospital. (2005)

Advisory Board, Schizophrenia International Research Society. (2005)

Member, Editorial Boards: International Journal of Neuropsychopharmacology, Schizophrenia Research. (2005)

Member, Royal Irish Academy (2003)

Foreign Corresponding Fellow, American College of Neuropsychopharmacology (1997)

Honours/Awards/Achievements

2013: Invitation Fellowship, Osaka University, Japan, Japan Society for the Promotion of Science, Tokyo, Japan

2013: Guest Professor, Osaka University, Tokyo, Japan

2012: Basic Science Award, Schizophrenia International Research Society

2012: Invitation Fellowship, Nihon University, Tokyo, Japan, Japan Society for the Promotion of Science, Tokyo, Japan

2004: Lilly Neuroscience Award, Collegium Internationale NeuroPsychopharmacologicum

2003: Election to membership, Royal Irish Academy

2000: Visiting Professor, Nihon University, Tokyo, Japan

1999: John Cade Lecturer, Mental Health Resarch Institute/University of Melbourne, Australia

1997: Foreign Corresponding Fellowship, American College of Neuropsychopharmacology

1996: Award of Merit for Pharmacology & Toxicology, Royal Irish Academy

1991: Graves Medallist, Royal Academy of Medicine in Ireland

1988: Merck Sharp & Dohme Research Prize, British Association for Psychopharmacology

1987: Conway Medallist, Royal Academy of Medicine in Ireland

Intra-Institutional Collaborations

Jacey-Lynn Minoi, RCSI, IrelandKieran Murphy, RCSI, IrelandNnamdi Nkire, RCSI, IrelandSarah Prasad, RCSI, Ireland
The analysis of three-dimensional facial dysmorphology and the pathobiology of psychosis.
(Oct 2009)

Mary Cannon, RCSI, IrelandNiamh Clarke, RCSI, IrelandDavid Cotter, RCSI, IrelandLieve Desbonnet, RCSI, IrelandMark Dunleavy, RCSI, IrelandDavid Henshall, RCSI, IrelandClaire O’Leary, RCSI, IrelandColm O’Tuathaigh, RCSI, Ireland
Targeted disruption of genes related to neuropsychiatric disease and translational phenotypes.
(Jun 2008)

Robin Hennessy, RCSI, IrelandKieran Murphy, RCSI, IrelandFergal Malone, RCSI, IrelandDavid Cotter, RCSI, IrelandDavid Croke, RCSI, IrelandColm O'Tuathaigh, RCSI, Ireland
3D surface imaging and geometric morphometrics.
(Mar 2006)

Alice Stanton, RCSI, IrelandKieran Murphy, RCSI, Ireland
Retinal microvascular changes in Schizophenia
(Mar 2006)

Kieran Mutphy, RCSI, Ireland
Resource for Psychosis Genomics Ireland.
(Mar 2006)

David Croke, RCSI, IrelandColm O'Tuathaigh, RCSI, IrelandDaniela Babovic, RCSI, Ireland
Dopamine receptor subtype and associated transduction mutants.
(Mar 2006)

Colm O'Tuathaigh, RCSI, IrelandDaniela Babovic, RCSI, IrelandKerstin Hakansson, RCSI, IrelandDavid Croke, RCSI, IrelandDavid Cotter, RCSI, IrelandMary Cannon, RCSI, Ireland
Mutant models of neuropsychiatric disease.
(Mar 2006)

Robin Hennessy, RCSI, Ireland
Epidemiology and pathobiology of schizophrenia and bipolar disorder.
(Mar 2006)

National Collaborations

Brendan Guilfoyle, Institute of Technology Tralee, Ireland ; Kevin Hayes, University of Limerick, Ireland ; Nnamdi Nkire,, Cavan-Monaghan Mental Health Service, Ireland ; Eadbhard O’Callaghan, DETECT/UCD, Ireland ; Vincent Russell, Cavan-Monaghan Mental Health Service, Ireland ; Paul Whelan, Dublin City University, Ireland
The analysis of three-dimensional facial dysmorphology and the pathobiology of psychosis.
(Oct 2009)

Aiden Corvin, Trinity College Dublin, Ireland ; Michael Gill, Trinity College Dublin, Ireland ; Kevin Mitchell, Trinity College Dublin, Ireland ; Daniela Tropea, Trinity College Dublin, Ireland
Targeted disruption of genes related to neuropsychiatric disease and translational phenotypes.
(Jun 2008)

Paul Wheland, DCU, Ireland ; Shane O'Mara, TCIN, Dublin, Ireland ; Martin Leahy, UL,
3D surface imaging and geometric morphometrics.
(Mar 2006)

Michael Gill, TCD, Ireland ; Aiden Corvin, TCD, Ireland
Resource for Psychosis Genomics Ireland .
(Mar 2006)

Karen Fleming, Cavan-Monaghan Mental Health Service, Ireland ; Clodagh Collins, Cavan-Monaghan Mental Health Service, Ireland ; Vincent Russell, Cavan-Monaghan Mental Health Service, Ireland
Resource for Psychosis Genomics Ireland
(Mar 2006)

Kevin Mitchell, TCD, Ireland
Mutant models of neuropsychiatric disease.
(Mar 2006)

Eadbhard O'Callaghan, UCD, Ireland
Epidemiology and pathobiology of schizophrenia and bipolar disorder.
(Mar 2006)

Tara Kingston, Cavan-Monaghan Mental Health Service, Ireland ; Vincent Russell, Cavan-Monaghan Mental Health Service, Ireland ; Conall Larkin, St. John of God Hospital, Dublin, Ireland
Epidemiology and pathobiology of schizophrenia and bipolar disorder.
(Mar 2006)

Kevin Hayes, UL, Ireland ; Brendan Guilfoyle, Institute of Technology, Tralee, Ireland
3D surface imaging and geometric morphometrics.
(Jan 1960)

International Collaborations

Adrian Bowman, University of Glasgow, UK ; Ashraf Ayoub, University of Glasgow, UK ; Stanislav Katina,, University of Glasgow, UK ; Paul Siebert, University of Glasgow, UK
The analysis of three-dimensional facial dysmorphology and the pathobiology of psychosis.
(Oct 2009)

John Drago, University of Melbourne, Australia ; Joseph Gogos, Columbia University, New York, USA ; Richard Harvey, University of New South Wales, Sydney, Australia ; Maria Karayiorgou, Columbia University, New York, USA ; Noriaki Koshikawa, Nihon University, Tokyo, Japan ; Katsunori Tomiyama, Nihon University, Tokyo, Japan
Targeted disruption of genes related to neuropsychiatric disease and translational phenotypes.
(Jun 2008)

Peter Hammond, University of London, UK ; Adrian Bowman, University of Glasgow, Scotland, Scotland ; Christopher Klingenberg, University of Manchester, UK ; Peggy Nopoulos, University of Iowa, USA ; Lynn Selemon, Yale University, USA ; Richard Harvey, University of New South Wales, Australia ; Maria Karayiorgou, Rockefeller University, USA ; Joesph Gogos, Columbia University, USA
3D surface imaging and geometric morphometrics.
(Mar 2006)

John Drago, Howard Florey Institute, University of Melbourne, Australia ; Alan Fienberg, Rockefeller University, USA ; David Grandy, Oregon Health and Science University, USA ; Paul Greengard, Rockefeller University, USA ; Noriaki Koshikawa, Nihon University, Japan ; Malcolm Low, Oregon Health and Science University, USA ; Marcelo Rubinstein, University of Buenos Aires, Argentina ; David Sibley, National Institute of Neurological Disorders and Stroke, USA ; David Grandy, Oregon Health and Science University, USA ; Paul Greengard, Rockefeller University, USA ; Noriaki Koshikawa, Nihon University, Japan ; Malcolm Low, Oregon Health and Science University, USA ; Marcelo Rubinstein, University of Buenos Aires, Argentina ; David Katsunori Sibley Tomiyama, National Institute of Neurological Disorders and Stroke, Nihon University, USA, Japan
Dopamine receptor subtype and associated transduction mutants.
(Mar 2006)

John Drago, Howard Florey Institute, University of Melbourne, Australia ; Joesph Gogos, Columbia University, USA ; Richard Harvey, University of New South Wales, Australia ; Malcolm Horne, Howard Florey Institute, University of Melbourne, Australia ; Maria Karayiorgou, Rockefeller University, USA ; Noriaki Koshikawa, Nihon University, Japan ; Katsunori Tomiyama, Nihon University, Japan
Mutant models of neuropsychiatric disease.
(Mar 2006)

Keynote Lecture

Waddington JClosing the translational gap between mutant mouse models and the clinical reality of psychotic illness.
International Behavioral Neuroscience Society, 23rd Annual Meeting, Las Vegas, Nevada, USA. (Jun 2014)

Invited Lecture

Waddington JTranslational studies of epistasis: phenotypic comparisons between mice mutant for either or both of two schizophrenia risk genes.
International Conference on Schizophrenia Research, Colorado Springs, USA. (Mar 2015)

Waddington JUsing knockout (KO) mice to investigate mechanisms of disease: gene-environment and gene-gene interactions.
Nihon University School of Dentistry, Tokyo, Japan. (Nov 2014)

Waddington JGenes, ’missing heritability’ and epistasis in risk for psychosis: clinical and translational mutant mouse studies.
Nagoya University School of Medicine and Fujita Health University School of Medicine, Nagoya, Japan. (Nov 2014)

Waddington JGene-environment and gene-gene interactions in mechanisms of disease: studies using knockout (KO) mice.
School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan (Oct 2014)

Waddington JThe use of knockout (KO) mice to study gene-environment and gene-gene interactions in mechanisms of disease.
Nihon University School of Dentistry at Matsudo, Chiba, Japan. (Oct 2014)

Waddington JClosing the translational gap between mutant mouse models and the clinical reality of psychotic illness.
International Behavioral Neuroscience Society, 23rd Annual Meeting, Las Vegas, Nevada, USA. (Jun 2014)

Waddington JCortical vs subcortical D1 dopamine receptor function and D1-glutamate interactions in schizophrenia-related phenotypic effects: mutant mouse models.
Symposium on New Vistas on the D1 Receptor: Implications of Novel Therapeutics. Society of Biological Psychiatry, 69th Annual Scientific Meeting, New York, USA. (May 2014)

Waddington JTopographies of movement disorder studied in patients with schizophrenia and in mice mutant for genes associated with risk for schizophrenia.
University Hospital of Psychiatry, Bern, Switzerland. (Mar 2014)

Waddington JThe genetics and psychobiology of psychotic illness: what diaspora of diagnoses and dimensions are we trying to treat?
Brixia International Conference on Emerging Issues in the Pharmacological Treatment of Psychiatric Disorders, Brescia, Italy. (Jun 2013)

Waddington JModelling schizophrenia: the challenges of homology and translation to therapeutic targets.
Brixia International Conference on Emerging Issues in the Pharmacological Treatment of Psychiatric Disorders, Brescia, Italy. (Jun 2013)

Waddington JClinical characteristics and functional outcome following a first psychotic episode in major depressive disorder.
Symposium on Major Depressive Disorder with Psychotic Features: Clues to the Dimensionality and Pathobiology of Psychosis. World Congress of Biological Psychiatry, Kyoto, Japan. (Jun 2013)

Waddington JModelling gene x gene interactions in schizophrenia using mutant models of gene disruption.
Symposium on Modelling Complex Interactions between Etiologically-related Factors over the Lifetime Trajectory of Schizophrenia. International Congress Schizophrenia Research, Florida, USA. (Apr 2013)

Waddington JGenetic models of psychiatric disorders: phenotyping mutant mice.
ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe, Nice, France. (Mar 2013)

Waddington JMutant mouse models: genotype-phenotype relationships to negative symptoms in psychosis.
10th Internatonal meeting on The Early Phases of Psychosis: Negative and Deficit Symptoms in Psychosis, Santander, Spain. (Jun 2012)

Waddington JSpontaneous involuntary movements as an integral component of network dysfunction in schizophrenia.
Symposium on Motor Symptoms as an Intrinsic Component of Schizophrenia pathobiology. European Conference on Schizophrenia Research, Berlin, Germany. (Sep 2011)

Waddington JInvestigating the origins and clinical diversity of psychotic illness.
Research and Evaluation Study Day, St. John of God Hospital, Co. Dublin. (Sep 2011)

Waddington JWhich aspects of schizophrenia can be modeled in mutant mice?
SYSGENET Workshop on Human and Mouse Cross-Species Research on Schizophrenia, Bomedicum, Helsinki, Finland. (Jun 2011)

Waddington JBehavioural phenotyping.
European Summer School on Behavioural Pharmacology, University of Utrecht, the Netherlands. (Jun 2011)

Waddington JGene-environment interactions in NRG1 and COMT mutants across the developmental trajectory of schizophrenia: biological and psychosocial Adversities.
Symposium on Translational Research in Gene-Environment Interactions in Psychiatry, Society of Biological Psychiatry, San Francisco, USA. (May 2011)

Waddington JChallenges in the use of mutant models for translating the neurobiology and function of schizophrenia – related gene.
Symposium on Translating the Neurobiology of Genes in Psychosis: from Mmolecular Signaling to Behavior, World Congress of Biological Psychiatry, Prague, Czech Republic. (May 2011)

Waddington JBiological and psychosocial adversities across time points relevant to the putative developmental trajectory of schizophrenia: gene environment interactions in NRG1 and COMT mutants?
Symposium on Gene and Environment Interplay in Schizophrenia: Basic and Clinical Advancements. International Congress on Schizophrenia Research, Colorado Springs, USA. (Apr 2011)

Waddington JDiagnostic diversity vs underlying unity in first episode psychosis: challenges for the clinical concept and genetically modified mouse models.
Winter Workshop on Psychoses, Innsbruck, Austria. (Feb 2011)

Waddington JMutation of genes regulating brain development: behavioural phenotype includes altered pain sensitivity.
Department of Pharmacology and Dental Research Centre, Nihon University School of Dentristry, Tokyo, Japan. (Sep 2010)

Waddington JHow far does animal model study reach?
Symposium on Mechanisms of Cognitive Dysfunction in Schizophrenia – Tidemark and Future Perspective. Neuro2010, Kobe, Japan. (Sep 2010)

Waddington JMutants in translation: can new models of schizophrenia provide new insight and targets?
Conference on New approaches and Targets in Psychiatry. World Congress of Basic and Clinical Pharmacology, Copenhagen, Denmark. (Jul 2010)

Waddington JModelling negative symptoms of schizophrenia in mutant mice: the psychopathological and functional challenge.
Symposium on Phenotypic Relationships to Domains of Psychopathology in Mutant Mouse Models of Psychosis, CINP Congress, Hong Kong, China. (Jun 2010)

Waddington JBehavioural phenotyping.
European summer School on Behavioural Pharmacology, University of Utrecht, the Netherlands. (Jun 2010)

Waddington JTM-domain neuregulin-1 mutants: ethological, social, cognitive and neurological phenotypes in relation to schizophrenia.
Symposium on Mouse Models on Neuregulin Signaling and their Relevance to Schizophrenia, Society of Biological Psychiatry, New Orleans, USA. (May 2010)

Waddington JPsychopathological, cognitive and morphological phenotypes in relation to schizophrenia risk genes: the example of neuregulin 1.
Symposium on Mutant Models and Psychosis at the Crossroads: a Critical Re-evaluation of Techniques and Translation, Schizophrenia International Research Society, Florence, Italy. (Apr 2010)

Waddington JSecond-generation antipsychotics: unitary or diverse mechanism(s) of action?
CINP Certificate in Psychopharmacology, Royal College of Physicians of Ireland, Dublin, Ireland, (Apr 2010)

Waddington J3D surface imaging of craniofacial dysmorphology as a 'window' on brain development in neuropsychiatric disease.
Departartment of Child, Adolescent & Adult Psychiatry, University Medical Center, Utrecht, The Netherlands. (Mar 2010)

Waddington JModelling schizophrenia: from neurobiology to genetically modified mice.
Workshop on Neurological and Psychiatric Disorders, from Neurobiology to Medicine: Focus on Schizophrenia, Sapienza - University of Rome, Italy. (Mar 2010)

Waddington JMutant models related to schizophrenia: phenotypic unity or endophenotypic diversity in behaviour?
Workshop on Translating Behaviour: Bridging Clinical and Animal Model Research, European Molecular Biology Laboratory, Heidelberg, Germany. (Nov 2009)

Waddington JTranslating brain mechanisms through gene disruption.
SFI Science Summit, Athlone, Ireland. (Nov 2009)

Waddington JMutant mouse models: psychopathology and translational psychopharmacology.
Symposium on Risk Variants through Biology to Treatment: Mapping the Challenges and the Potential, World Congress of Psychiatric Genetics, San Diego, USA. (Nov 2009)

Waddington JThe diversity of first episode psychosis and implications for early intervention: the Cavan-Monaghan study at 13 years.
Conference on Psychosis: Improving Outcome, St. John of God Hospital, Dublin, Ireland. (Oct 2009)

Waddington JDopamine in schizophrenia: becalmed or second wind.
Scotland Educational Meeting on From Cradle to Grave: New Understanding of the Epidemiology, Aetiology and Outcome of Schizophrenia, Dunblane, Scotland. (Oct 2009)

Waddington JKnockout, knockin and transgenic approaches for the study of neurological and psychiatric disorders.
Department of Pharmacology and Dental Research Centre, Nihon University School of Dentistry, Tokyo, Japan. (Sep 2009)

Waddington JMutant models related to schizophrenia: phenotypic unity or endophenotypic diversity?
Departments of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan. (Sep 2009)

Waddington JSecond-generation antipsychotics: unitary or diverse mechanism(s) of action?
Collegium Internationale Neuropsychopharmacologicum, Royal College of Physicians of Ireland, Dublin. (Apr 2009)

Waddington JTargeted deletion of dopamine receptor subtypes and genes associated with risk for psychosis: brain-behaviour relationships.
Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China. (Mar 2009)

Waddington JTargeted deletion of dopamine receptor subtypes and genes associated with risk for psychosis: brain-behaviour relationships.
Institute of Brain Functional Genomics, East China Normal University, Shanghai, China, Shanghai, China. (Mar 2009)

Waddington JTargeted deletion of dopamine receptor subtypes and genes associated with risk for psychosis: brain-behaviour relationships.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. (Mar 2009)

Waddington JBrain-behaviour relationships: dopamine receptor subtype knockouts and mice mutant for genes associated with schizophrenia.
GlaxoSmithKline, Harlow, United Kingdom. (Feb 2009)

Waddington JDopamine receptor subtype knockouts and mutation for genes associated with schizophrenia: brain-behaviour relationships.
Department of Pharmacology & Psychiobiology, Federal University of Sao Paulo, Brazil. (Feb 2009)

Waddington JThe totality of psychosis.
Conference on Search for the Causes of Schizophrenia, Sao Paulo, Brazil. (Feb 2009)

Waddington JChallenges and opportunities in behavioural approaches to discovering functionally selective drugs.
Symposium on Functional Selectivity of GPCRs: Pharmacological Treasure Chest or Experimental Quagmire?, American College of Neuropsychopharmacology, Scottsdale, USA. (Dec 2008)

Waddington JMutant phenotypes for genes associated with schizophrenia.
Symposium on Animal Models of Schizophrenia, Lilly Research Centre, Windlesham, UK. (Nov 2008)

Waddington JFrom developmental pathobiology to long-term outcome and treatment: the lifetime trajectory of schizophrenia.
Western Region Consultant Psychiatrists’ Association, Galway, Ireland. (Oct 2008)

Waddington JFunctional roles of genes associated with schizophrenia: mutant models.
Invited Lecture: Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan. (Sep 2008)

Waddington JPhenotypic evaluation of cognitive function and social behaviour in mutant mice with deletion of catechol-O-methyltransferase [COMT].
Department of Pharmacology and Dental Research Centre, Nihon University School of Dentistry, Tokyo, Japan. (Sep 2008)

Waddington JNeuregulin and the pathobiology of schizophrenia: studies in ‘knockout‘ mice.
Symposium on Gene-Environmental Interaction Affecting Animal and Human Behavior, Japanese Society for Neurochemistry, Toyama, Japan. (Sep 2008)

Waddington JThe lifetime trajectory of schizophrenia: from developmental pathobiology to long-term outcome and treatment.
Satellite Symposium on Long-Term Treatment of Schizophrenia: New Perspectives, European College of Neuropsychopharmacology, Barcelona, Spain. (Sep 2008)

Waddington JMutant models for genes associated with schizophrenia: psychopharmacological characterisation.
Symposium on Psychopharmacology, Neuroscience Ireland, Galway, Ireland. (Aug 2008)

Waddington JSchizophrenia susceptibility genes: mutant models and endophenotypes.
Workshop on Behavioural Genetics and its Relevance to Neuropsychiatric Disorders, European Behavioural Pharmacology Society, Cork, Ireland. (Aug 2008)

Waddington JMutation for genes associated with risk for schizophrenia: phenotypic characterisation
Symposium on How do Schizophrenia Genes Work? British Association for Psychopharmacolgy, Harrogate, UK. (Jul 2008)

Waddington JGenetic rodent models of schizophrenia.
Symposium on Animal Models, Schizophrenia International Research Society Conference, Venice, Italy. (Jun 2008)

Waddington JBehavioural phenotyping: mutants relating to neuropsychiatric disorders.
European Summer School on Behavioural Pharmacology, Oss, the Netherlands. (Jun 2008)

Waddington JMice mutant for genes related to schizophrenia: social behaviour and cognition
Workshop on Cross-Validation of Models in Preclinical Science, Winter Workshop on Schizophrenia, Montreux, Switzerland. (Feb 2008)

Waddington JMutation for genes associated with risk for schizophrenia: phenotypic effects related to psychosis and its treatment
Sahlgrenska Academy, University of Gothenburg, Sweden. (Dec 2007)

Waddington JPhenotypic studies in mutant models related to schizophrenia: translational approaches.
Organon Laboratories, Newhouse, Scotland. (Nov 2007)

Waddington JAn epidemiological and long-term outcome perspective on antipsychotic polypharmacy.
Symposium on Antipsychotic Polypharmacy for the Treatment of Schizophrenia, College of Neuropsychopharmacology, Vienna, Austria. (Oct 2007)

Waddington JPhenotypic studies in mice mutant for genes associated with risk for schizophrenia.
Riken Brain Science Institute, Saitama, Japan. (Sep 2007)

Waddington JNeuropsychiatric disorders involving orofacial dysfunction: mutant models of pathophysiology.
School of Dentistry and Dental Research Centre, Nihon University, Tokyo, Japan. (Sep 2007)

Waddington JPhenotypic studies in mutants related to psychosis: dopamine receptor subtypes and genes associated with risk for schizophrenia.
Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia. (Jul 2007)

Waddington JMutant mouse models to probe putative mechanisms of antipsychotic drug action: phenotypic behaviour.
Symposium on Dopamine/Serotonin Interactions in Psychosis: A Translational View, IBRO World Congress of Neuroscience, Melbourne, Australia. (Jul 2007)

Waddington JSchizophrenia and antipsychotic drug action: targeted deletion of dopamine receptor subtypes and risk genes.
Plenary lecture, Japanese Pharmacological Society, Tokyo, Japan (Jun 2007)

Waddington JSecond-generation antipsychotics: unitary or diverse mechanisms of action?
Certificate in Psychopharmacology, Collegium Internationale Neuropsychopharmacologicum, Royal College of Physicians of Ireland, Dublin, (Feb 2007)

Waddington JThe Cavan-Monaghan first episode study: apparent diversity as a clue to unity in psychosis?
Division of Psychiatry & Neuroscience, Queen’s University of Belfast, United Kingdom. (Dec 2006)

Waddington J3D laser surface imaging of cerebral-craniofacial dysmorphogenesis: a clue to the developmental origins of schizophrenia.
Bahrain Medical Society, Juffair, Bahrain, (Nov 2006)

Waddington JNeurodegenerative disease, neurodevelopmental disorder and mutant phenotypes.
Symposium on A Critical Assessment of Regeneration/Degeneration by Phenotyping, Howard Florey Institute, University of Melbourne, Australia (Sep 2006)

Waddington JMutant models of genes associated with neurological and psychiatric disorders: phenotypic characterisation.
Nihon University School of Dentistry, Tokyo, Japan (Sep 2006)

Waddington JMutant models of dopamine receptor subtype function and genes associated with schizophrenia.
Department of Psychiatry, Nara Medical University, Japan (Sep 2006)

Waddington JEpidemiology of first episode bipolar disorder.
Biennial Conference, International Society for Bipolar Disorders, Edinburgh, UK (Aug 2006)

Waddington JBehavioural phenotyping of mutant models: focus on schizophrenia and neuregulin ‘knockout’.
Symposium on Challenges in Constructing and Phenotyping Mutants Relevant to Neuropsychiatric Disorders, Congress of Collegium Internationale NeuroPsychopharmacologicum,, Chicago, USA. (Jul 2006)

Waddington JBehavioural phenotyping.
European Summer School on Behavioural Pharmacology, Oss, the Netherlands (Jun 2006)

Waddington JFirst episode schizophrenia, bipolar disorder and major depression with psychosis.
International Symposium on Schizophrenia, Oxford, UK. (May 2006)

Waddington JMice mutant for genes associated with risk for psychosis: phenotypic characterisation.
Symposium on Genetics of Psychosis, European Regional Conference of Collegium Internationale NeuroPsychopharmacologicum, Belfast, UK. (Apr 2006)

Waddington JPhenotypic assessment following ‘knockout’ of dopamine receptor subtypes and mutation for genes associated with neuropsychiatric disorders.
Tohoku University Graduate School of Medicine, Sendai, Japan (Sep 2005)

Waddington JReceptor subtype ‘knockout’ and mutation for genes associated with neuropsychiatric disorders: challenges in phenotypic assessment.
Department of Pharmacology, Nihon University School of Dentistry, Tokyo, Japan (Sep 2005)

Waddington JBehavioural phenotyping.
European Summer School on Behavioural Pharmacology, Oss, the Netherlands (Jun 2005)

Waddington JMethodological challenges in phenotyping mutants relating to neuropsychiatric disorders and their treatment.
Department of Genetics, Smurfit Institute, Trinity College Dublin, Ireland (Jan 2005)

Waddington JCraniofacial dysmorphology as an index of brain dysmorphogenesis in neuropsychiatric disorders of early origin.
Dental Research Centre, Nihon University, Tokyo, Japan (Nov 2004)

Waddington JIncidence and demographics of first episode psychosis in major depressive disorder among an epidemiologically complete population: the Cavan-Monaghan first episode study at 9 years.
Symposium on First Episode Psychosis in Major Depressive Disorder: A Neglected Entity? Conference of International Early Psychosis Association, Vancouver, Canada (Oct 2004)

Waddington JAccessing the embryology of developmental pathobiology in schizophrenia.
Research & Development Office,, Department of Health and Queen’s University of Belfast, Northern Ireland. (Sep 2004)

Waddington JTranslational impact of behavioural phenotyping.
Howard Florey Institute, University of Melbourne,, Australia. (Aug 2004)

Waddington JCraniofacial morphology by 3D laser surface scanning and its application to the study of dysmorphogenesis in neurodevelopmental disorders.
Anatomical Society of Great Britain and Ireland,, Cork, Ireland (Jul 2004)

Waddington JBehavioural pharmacology of second-generation antipsychotics and a new generation of preclinical models.
Symposium on Second Generation of Antipsychotic Drugs: From Bench to Bed, Collegium Internationale NeuroPsychopharmacologicum,, Paris, France. (Jun 2004)

Waddington JVisualisation of craniofacial dysmorphology in psychotic illness as a shape abnormality about the midline.
Symposium on The Midline as a Developmental Field and its Relationship to Dysmorphogenesis in Psychotic Illness, Collegium Internationale NeuroPsychopharmacologicum,, Paris, France. (Jun 2004)

Waddington JSecond-generation antipsychotics: do we have enough information to specify individual advantages and liabilities?
Meeting on The Changing Healthcare Environment,, Dublin, Ireland. (Jan 2004)

Waddington JSome new insights into the psychopharmacology of schizophrenia and bipolar affective disorder.
Symposium on Current Topics in Psychiatry, Dublin, Ireland (Oct 1987)

Waddington JNew selective D-l and D-2 dopamine receptor agonists as further probes for behavioural interactions between D-l and D-2 systems.
Symposium on Dopamine '87: Dopamine Systems and their Regulation, Satellite Meeting of 10th IUPHAR Congress, Hungerford Hill, Australia (Aug 1987)

Waddington JBehavioural effects of acute vs long-term treatments with selective antagonists of D-l and D-2 dopamine receptors.
Symposium on Dopamine Receptor Regulation: Functional, Behavioural and Clinical Aspects, 6th International Catecholamine Symposium, Jerusalem, Israel (Jun 1987)

Waddington JThe ageing brain, neuroleptic drugs and the enigma of schizophrenia.
Conway Review Lecture, Royal Academy of Medicine in Ireland, Belfast, N. Ireland (Jun 1987)

Waddington JDyskinesia and cognitive function in schizophrenia.
Symposium on Organic Correlates of Extrapyramidal Syndromes, American Psychiatric Association, Chicago, USA (May 1987)

Waddington JFunctional studies with new selective D-l and D-2 dopaminergic receptor agonists and antagonists.
Lilly Research Laboratories, Indianapolis, USA (May 1987)

Waddington JSelective D-l dopamine receptor agonists and antagonists, and the regulation of behaviour.
Abbott Laboratories, North Chicago, USA (May 1987)

Waddington JLong-term oral and depot neuroleptics and vulnerability to tardive dyskinesia: animal and clinical studies.
Medical Tribune Group Psychiatric Symposium, Jersey, Channel Islands (Apr 1987)

Waddington JNeuroleptic drugs and D-l dopamine receptors in human post-mortem brain.
University Clinic for Psychiatry, Innsbruck, Austria (Mar 1987)

Waddington JLong-term oral and depot neuroleptics and vulnerability to tardive dyskinesia: clinical and animal studies.
Medical Tribune Group Psychiatric Symposium, Amsterdam, Holland (Mar 1987)

Waddington JToxicity of long-term neuroleptic administration.
Symposium on Psychopharmacology & Toxicology, British Association for Psychopharmacology, Cardiff, Wales (Feb 1987)

Waddington JMotor consequences of D-l dopamine receptor stimulation and blockade.
Symposium on Basic Science of D-l and D-2 Dopamine Receptors, Collegium Internationale NeuroPsychopharmacologicum, San Juan, Puerto Rico (Dec 1986)

Waddington JCognitive dysfunction and vulnerability to tardive dyskinesia: treatment or illness?
Psychiatry Section, Royal Academy of Medicine in Ireland, Dublin, Ireland (Nov 1986)

Waddington JSome observations on the pharmacology of schizophrenia, and the therapeutic potential of selective D-l vs D-2 dopamine receptor antagonists.
Schizophrenia and Allied Conditions Committee Study Day, Medical Research Council, London, UK (Nov 1986)

Waddington JPET, a window on the brain. Pharmacology & Toxicology Society.
University College Dublin, Ireland (Nov 1986)

Waddington JInvoluntary movements in schizophrenia in relation to features of the illness and its treatment with neuroleptic polypharmacy and neuroleptic-anticholinergic combinations.
Aplenlandisches Psychiatrie Symposium, Seefeld, Austria (Sep 1986)

Waddington JPharmacological aspects relating to the issue of lithium-neuroleptic neurotoxic interactions.
Workshop on Combined Lithium and Neuroleptic Therapy for Manic-Depressive Illness, World Psychiatric Association Regional Symposium, Copenhagen, Denmark (Aug 1986)

Waddington JD-l dopaminergic function and regulation of the intensity of D-2 stimulated behaviour.
Symposium on Molecular Mechanism of Action of Antiparkinsonian drugs, Canadian Congress of Neurological Sciences, Ontario, Canada (Jun 1986)

Waddington JMovement disorder and schizophrenic deterioration.
Symposium on Tardive Dyskinesia, Amererican Psychiatric Association, Washington DC, USA (May 1986)

Waddington JInvestigation of the D-l dopamine receptor using new selective agents, and some clinical implications.
National Institute of Neurological, Communicative Disorders and Stroke, Experimental Therapeutics Branch, Washington DC, USA (May 1986)

Waddington JSchizophrenia and tardive dyskinesia with genetic considerations in an extensive Irish pedigree.
Postgraduate Lecture, St. Patrick's Hospital, Dublin, Ireland (May 1986)

Waddington JThe psychopharmacology of dopamine receptors.
Department of Pharmacology, Trinity College, Dublin, Ireland (Mar 1986)

Waddington JTardive dyskinesia.
Department of Psychiatry, Long Island Jewish-Hillside Medical Centre., New York, USA (Mar 1986)

Waddington JThe D-l dopamine receptor: a re-evaluation using new selective drugs.
Wellcome Research Laboratories, Beckenham, UK (Feb 1986)

Waddington JClinical Correlates of dyskinesia.
Winter Workshop on Schizophrenia, Schladming, Austria (Jan 1986)

Waddington JStructural analogues of SCH 23390 as new probes for behavioural interactions between D-l and D-2 dopaminergic function.
Symposium on Biochemical and Functional Studies of D-l Dopamine Receptors, American College of Neuropsychopharmacology, Maui, Hawaii (Dec 1985)

Waddington JFactors associated with late-onset side effects of neuroleptic maintenance medication.
Symposium on Current Views of Long-Term Neuroleptic Maintenance Medication, Nuffield Centre for Health Services Studies, University of Leeds, UK (Nov 1985)

Waddington JDyskinesias: relative contribution of neuroleptic treatment and the disease process.
Symposium on Schizophrenia: The Nature of the Disease Process, Royal College of Psychiatrists, London, UK (Nov 1985)

Waddington JPharmacological and clinical actions of neuroleptics in relation to ageing.
Symposium on Psychogeriatrics, Antwerp, Belgium (Oct 1985)

Waddington JNeurochemistry of Parkinson's disease.
Symposium on Parkinson's Disease. Royal Academy of Medicine in Ireland, Dublin, Ireland (Oct 1985)

Waddington JLocomotor behaviours in response to novel selective D-l and D-2 dopamine receptor agonists and antagonists.
Satellite Symposium on Locomotor Behaviour: Neuropharmacological Substrata of Motor Activation, American Society for Neuroscience, Dallas, USA (Oct 1985)

Waddington JThe neglected D-l dopamine receptor and the impact of new selective drugs.
Department of Pharmacology, University of North Carolina, Chapel Hill, USA (Oct 1985)

Waddington JSpontaneous and drug-induced dyskinesias in rodents in relation to ageing and long-term neuroleptic treatment: relationship to tardive dyskinesia.
Symposium on Animal Models of Tardive Dyskinesia, World Congress of Biological Psychiatry, Philadelphia, USA (Sep 1985)

Waddington JA re-appraisal of D-l dopamine receptor function.
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, USA (Sep 1985)

Waddington JBiochemical and pharmacological studies of new selective antagonists of brain D-l and D-2 dopamine receptors.
Roche Research Centre, Nutley, New Jersey, USA (Sep 1985)

Waddington JVulnerability to involuntary movements in schizophrenia: relative contributions of neuroleptic exposure and disease process.
Symposium on Recent Advances in Biological Psychiatry, Northern Ireland Council for Postgraduate Medical Education, Belfast, Ireland (Sep 1985)

Waddington JAbnormal involuntary movements (tardive dyskinesia) in relation to long-term neuroleptic treatment.
Tyrone & Fermanagh Hospital, Omagh, N. Ireland (Jul 1985)

Waddington JThe clinical pharmacology of neuroleptics: receptor or non-receptor mediated events?
Northern Ireland Division, Royal College of Psychiatrists, Downpatrick, N. Ireland (May 1985)

Waddington JReceptor vs. non-receptor mediated events and the clinical effects of the neuroleptics.
Symposium on Neuroleptic Agents in Psychoses: from Receptor Binding to Clinical Practice, Manchester, UK (May 1985)

Waddington JNeurotransmitter receptors and ageing.
Symposium on Pharmacology and Therapeutics in the Elderly., Dublin. Ireland (Mar 1985)

Waddington JNeuroleptic drugs, the ageing brain and the riddle of schizophrenia.
University College Dublin, Biochemistry, Pharmacology & Toxicology Society, Dublin, Ireland (Feb 1985)

Waddington JAbnormal involuntary movements and long-term neuroleptic treatment in animals and man.
National Institute of Mental Health, St. Elizabeth's Hospital, Washington DC, USA (Oct 1984)

Waddington JFactors associated with tardive and spontaneous dyskinesia in man and animals.
Department of Psychiatry, Oregon Health Sciences University, Portland, USA (Oct 1984)

Waddington JAnimal and clinical studies of factors associated with tardive and spontaneous dyskinesia.
Department of Psychiatry, Long Island Jewish-Hillside Medical Centre, New York, USA (Oct 1984)

Waddington JA reappraisal of abnormal, involuntary movements ('tardive' dyskinesia) in schizophrenia.
Symposium on the Neurobiology of Dopamine Systems, Leed, UK (Jul 1984)

Waddington JTardive dyskinesia.
Department of Psychiatry at St. Lars Hospital, University of Lund, Sweden (May 1984)

Waddington JAssociation of intellectual impairment, negative symptoms and ageing with abnormal, involuntary movements ('tardive' dyskinesia) in schizophrenia.
Symposium on Tardive Dyskinesia, American Psychiatric Association, American Psychiatric Association, Los Angeles, USA (May 1984)

Waddington JMovement disorders, dopamine and the interaction between ageing and long-term neuroleptic treatment.
Department of Psychiatry and Andrus Gerontology Centre, University of Southern California School of Medicine, Los Angeles, USA (May 1984)

Waddington JBehavioural studies on movement disorder during ageing and long-term treatment with neuroleptic drugs.
Department of Psychology, University of California, Los Angeles, USA (Mar 1984)

Waddington J, Behavioural studies of dopaminergic function in the mammalian brain.
Research Seminar, University College Dublin, Ireland (Feb 1984)

Waddington JMotor function and central nervous system changes in ageing and senescence.
Irish Gerontological Society, Dublin, Ireland (Feb 1984)

Waddington JStereoselective interactions of benzazepine derivatives with D-l and D-2 dopamine receptors.
Smith Kline & French Laboratories, Philadelphia, USA (Nov 1983)

Waddington JStereoselective interactions of benzazepine derivatives with D-l and D-2 dopamine receptors.
Schering Plough Research Division, New Jersey,USA (Nov 1983)

Waddington JIs the treatment of schizophrenia worse than the disease?
Psychiatry Registrars Meeting, Belfast, Northern Ireland (Oct 1983)

Waddington JAnimal models in tardive dyskinesia: is there a clinical relevance?
Department of Psychiatry, University of Lund, Sweden (Jun 1983)

Waddington JAnimal models in tardive dyskinesia: is there a clinical relevance? Department
Department of Psychiatry, Lilhagen Hospital, University of Gothenburg, Sweden (Jun 1983)

Waddington JStudies on the pathophysiology of tardive dyskinesia and Huntington's chorea.
Symposium on Recent Advances in Neurology, Cork, Ireland (May 1983)

Waddington JRecent studies on the pathophysiology of Huntington's disease.
Royal Academy of Medicine in Ireland, Neurological Sciences section, Dublin, Ireland (Feb 1983)

Waddington JPharmacological management of schizophrenia: is the treatment worse than the disease?
Institute for Clinical Science and Research, Dublin, Ireland (Dec 1982)

Waddington JLong-term neuroleptic treatment and the pathophysiology of tardive dyskinesia.
Maryland Psychiatric Research Centre, University of Maryland School of Medicine, USA (Nov 1982)

Waddington JLong-term neuroleptic treatment and the pathophysiology of tardive dyskinesia.
National Institute of Mental Health, Bethesda, USA (Nov 1982)

Waddington JLong-term neuroleptic treatment and the pathophysiology of tardive dyskinesia.
Department of Psychiatry, University of Chicago School of Medicine, Chicago, USA (Nov 1982)

Waddington JAnimal models in tardive dyskinesia: is there a clinical relevance?
Animal models in tardive dyskinesia: is there a clinical relevance?, Stockholm, Sweden (Nov 1982)

Waddington JAnimal models in tardive dyskinesia: is there a clinical relevance?
Department of Psychiatry and Neurochemistry, St. Jorgen's Hospital, University of Gothenburg, Sweden (Nov 1982)

Waddington JRecent studies on the brain benzodiazepine receptor.
Symposium on Third Generation Hypnotics, Dublin, Ireland (Oct 1982)

Waddington JSome consequences of very long-term neuroleptic treatment in animals.
Ciba-Geigy Research, Basel, Switzerland (Apr 1982)

Peer Reviewed Publications

Rodriguez-Alvarez N, Jimenez-Mateos EM, Dunleavy M, Waddington JL, Boylan GB, Henshall DC
Effects of hypoxia-induced neonatal seizures on acute hippocampal injury and later-life seizure susceptibility and anxiety-related behavior in mice.
Neurobiol Dis. 2015;83:100-114.     PMID: 26341542     (Sep 2015)

Sukno FM, Waddington JL, Whelan PF
3-D facial landmark localization with asymmetry patterns and shape regression from incomplete local features.
IEEE Trans Cybern. 2015;45(9):1717-30.     PMID: 25314716     (Sep 2015)

Jiang L, O’Leary C, Kim HA, Parish CL, Massalas J, Waddington JL, Ehrlich ME, Schutz G, Gantois I, Lawrence AJ, Drago J
Motor and behavioural phenotype in conditional mutants with targeted ablation of cortical D1 dopamine receptor-expressing cells.
Neurobiol Dis. 2015;76:137-58.     PMID: 2568453     (Apr 2015)

Nkiri N, Sardinha S, Nwosu B, McDonough CM, De Coteau PA, Duffy I, Waddington JL, Russell V
Evaluation of knowledge and attitudes among primary care physicians in Cavan-Monaghan as 'gatekeepers-in-waiting' for the introduction of Carepath for Overcoming Psychosis Early (COPE).
Early Interv Psychiatry. 2015;9(2):141-50.     PMID: 23855315     (Apr 2015)

Prasad S, Katina S, Hennessy RJ, Murphy KC, Bowman AJ, Waddington JL
Craniofacial dysmorphology in 22q11.2 deletion syndrome by 3D laser surface imaging and geometric morphometrics: illuminating the developmental relationship to risk for psychosis.
Am J Med Genet A. 2015;167A(3):529-36.     PMID: 25691406     (Mar 2015)

Ikeda H, Adachi K, Fujita S, Tomiyama K, Saigusa T, Kobayashi M, Koshikawa N, Waddington JL
Investigating complex basal ganglia circuitry in the regulation of motor behaviour, with particular focus on orofacial movement.
Behav Pharmacol. 2015;26(1-2):18-32.     PMID: 25485640     (Feb 2015)

O’Tuathaigh CM, Waddington JL
Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness.
Neurosci Biobehav Rev. 2015; Epub ahead of print.     PMID: 25616181     (Jan 2015)

Fountoulakis KN et al including Grady A, Waddington J
Relationship of suicide rates to economic variables in Europe: 2000-2011.
Br J Psychiatry. 2014; 205:486-96.     PMID: 25359926     (Dec 2014)

Gusev A, et al including Waddington J
Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases.
Am J Hum Genet. 2014;95(5):535-52     PMID: 25439723     (Nov 2014)

O'Callaghan MJ, Bay-Richter C, O'Tuathaigh CM, Heery DM, Waddington JL, Moran PM
Potentiation of latent inhibition by haloperidol and clozapine is attenuated in dopamine D2 receptor (Drd-2)-deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms?
J Psychopharmacol. 2014;28:973-7.     PMID: 25122042     (Oct 2014)

O’Leary C, Desbonnet L, Clarke N, Petit E, Tighe O, Lai D, Harvey R, Waddington JL. O’Tuathaigh, C
Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1.
Neuroscience 2014; 277, 294-305.     PMID: 24969132     (Sep 2014)

Schizophrenia Working Group of the Psychiatric Genomics Consortium (including Waddington J)
Biological insights from 108 schizophrenia-associated genetic loci.
Nature. 2014;511:421-7.     PMID: 25056061     (Jul 2014)

O'Tuathaigh CM, Gantois I, Waddington JL
Genetic dissection of the psychotomimetic effects of cannabinoid exposure.
Prog. Neuropsychopharmacol. Biol. Psychiatry 2014;52:33-40.     PMID: 24239593     (Jul 2014)

Morris DW, Pearson RD, Cormican P, Kenny EM, O'Dushlaine CT, Lemieux Perreault LP, inc., Waddington JL, et al; International Schizophrenia Consortium; SGENE+ Consortium, Wellcome Trust Case Control Consortium 2, Kendler KS, Gill M, Riley BP, Spencer CC, Corvin A
An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis.
Hum Mol Genet. 2014;23:3316-26.     PMID: 24474471     (Jun 2014)

O'Tuathaigh CM, Desbonnet L, Waddington JL
Genetically modified mice related to schizophrenia and other psychoses: Seeking phenotypic insights into the pathobiology and treatment of negative symptoms.
Eur. Neuropsychopharmacol. 2014;24:800-821.     PMID: 24290531     (May 2014)

Kim HA, Jiang L, Madsen H, Parish CL, Massalas J, Smardencas A, O'Leary C, Gantois I, O'Tuathaigh C, Waddington JL, Ehrlich ME, Lawrence AJ, Drago J
Resolving pathobiological mechanisms relating to Huntington disease: Gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells.
Neurobiol Dis. 2014;62:323-37.     PMID: 24135007     (Feb 2014)

Omer S, Kirkbride JB, Pringle DG, Russell V, O'Callaghan E, Waddington JL
Neighbourhood-level socio-environmental factors and incidence of first episode psychosis by place at onset in rural Ireland: The Cavan-Monaghan First Episode Psychosis Study CAMFEPS.
Schizophr. Res. 2014;152:152-157.     PMID: 24342585     (Jan 2014)

Mullin AP, Gokhale A, Moreno-De-Luca A, Sanyal. S, Waddington JL, Faundez V
Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes.
Transl Psychiatry. 2013;3:e329     PMID: 24301647     (Dec 2013)

Kingston T, Scully PJ, Browne DJ, Baldwin PA, Kinsella A, Russell V, O'Callaghan E. & Waddington JL
Diagnostic trajectory, interplay and convergence/divergence across all 12 DSM-IV psychotic diagnoses: 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
Psychol. Med. 2013;1-11.     PMID: 23480983     (Dec 2013)

Tomiyama K, Kato R, Hara Y, Kobayashi M, Mishina M, Yanagawa Y, Kinsella A, Koshikawa N. & Waddington JL
Phenotypic characterization of orofacial movement topography in mutants with disruption of amino acid mechanisms: Glutamate N2A/B/D GluRå1/2/4 subtypes and the GABA synthesizing enzyme GAD65.
Neuroscience 2013;250:743-54     PMID: 23892010     (Oct 2013)

O'Tuathaigh CM, Moran PM. & Waddington JL
Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological 'minefield'.
Cell Tissue Res. 2013;354:247-257.     PMID: 23715722     (Oct 2013)

Waddington JL, Buckley PF
Psychotic depression: an under-appreciated window to explore the dimensionality and pathobiology of psychosis.
Schizophr Bull. 2013;39:754-755.     PMID: 23709405     (Jul 2013)

Owoeye O, Kingston T, Scully PJ, Baldwin P, Browne D, Kinsella A, Russell V, O'Callaghan E, Waddington JL
Epidemiological and clinical characterisation following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar disorder.
Schizophr Bull. 2013;39:756-765.     PMID: 23716714     (Jul 2013)

Sukno FM, Waddington JL. & Whelan PF
Rotationally invariant 3D shape contexts using asymmetry patterns.
In: Proc. 8th International Conference on Computer Graphics Theory and Applications, Barcelona, Spain, pp 7-17, 2013.     PMID: n/a     (Jun 2013)

Sukno F M, Waddington JL. & Whelan PF
Craniofacial landmark localisation with asymmetry patterns shape objects.
In: BioPIC 2013 BioPhotonics and Imagining conference, Dublin, Ireland, pp 25-27, 2013     PMID: n/a     (Jun 2013)

Sukno FM, Waddington JL. & Whelan PF
Compensating inaccurate annotations to train 3D facial landmark localization models.
In: Proc. Workshop on 3D Face Biometrics, Shanghai, China, IEEE Xplore Digital Library, pp 1-8, 2013.     PMID: n/a     (Jun 2013)

Sukno FM, Waddington JL. & Whelan PF
3D Facial landmark localization using combinatorial search and shape regression.
In: (Bebis, G. et al, Eds.) Computer Vision - ECCV Springer-Verlag, Berlin 2012;7583, pp 32-41.     PMID: N/A     (May 2013)

Kingston T, Scully PJ, Browne DJ, Baldwin PA, Kinsella A, Russell V, O'Callaghan E. & Waddington JL
Diagnostic trajectory, interplay and convergence/divergence across all 12 DSM-IV psychotic diagnoses: 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
Psychol Med. 2013;1-11.     PMID: 23480983     (Mar 2013)

Bay-Richter C, O'Callaghan MJ, Mathur N, O'Tuathaigh CM, Heery DM, Fone KC, Waddington JL, & Moran PM
D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors.
Neuropsychopharmacology 2013;38:1512-1520.     PMID: 23422792     (Feb 2013)

Cummings E, Donohoe G, Hargreaves A, Moore S, Fahey C, Dinan TG, McDonald C, O'Callaghan E, O'Neill FA, Waddington JL, Murphy KC, Morris DW, Gill M. & Corvin A
Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137.
Neurosci Lett. 2013;532:33-8.     PMID: 22982201     (Jan 2013)

van der Werf M, Hanssen M, Köhler S, Verkaaik M. & Verhey FR. RISE Investigators including Baldwin P. & Waddington JL, van Winkel R, van Os J, Allardyce J
Systematic review and collaborative recalculation of 133 693 incident cases of schizophrenia.
Psychol Med. 2012;1-8.     PMID: 23244442     (Dec 2012)

Desbonnet L, O’Tuathaigh CMP. & Waddington JL
Modelling schizophrenia: uncovering novel therapeutic targets.
Exp Rev Clin Pharmacol. 2012;5:667-76.     PMID: 23234324     (Nov 2012)

Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Gervin M, Macklin E, Kinsella A, Larkin C, Waddington JL, O’Callaghan E
Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years.
Schizophr Res. 2012; 141(2-3):215-21.     PMID: 23006501     (Nov 2012)

O'Tuathaigh CMP, Clarke G, Walsh J, Desbonnet L, Petit E, O'Leary C, Tighe O, Karayiorgou M, Gogos JA, Dinan TD, Cryan J, Waddington JL
Genetic vs pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes.
Int J Neuropsychopharmacol. 2012;15:1331-42     PMID: 22074909     (Oct 2012)

Tomiyama K, Drago J, Waddington JL, Koshikawa N
Constitutive and conditional mutant mouse models for understanding dopaminergic regulation of orofacial movements: emerging insights and challenges.
J Pharmacol. Sci. 2012;119: 297-301.     PMID: 22863668     (Aug 2012)

Irish Schizophrenia Genomics Consortium including Waddington JL and the Wellcome Trust Case Control Consortium 2
Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia.
Biol Psychiatry. 2012;72:620–628.     PMID: 22883433     (Aug 2012)

Adachi K, Kobayashi M, Kawasaki T, Yokoyama C, Waddington JL, Sakagami H, Onoe H, Koshikawa N
Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson's disease.
J Neural Transm. 2012;119:933-41.     PMID: 22350537     (Aug 2012)

Jimenez-Mateos E M, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, Sano T, O'Tuathaigh C, Waddington JL, Prenter S, Delanty N, Farrell MA, O'Brien DF, Conroy RM, Stallings RL, Defelipe J, Henshall DC
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects.
Nat. Med. 2012; 18:1087-1094.     PMID: 22683779     (Jul 2012)

Desbonnet L, O'Tuathaigh C, Clarke G, O'Leary C, Petit E, Clarke N, Tighe O, Lai D, Harvey N, Cryan JF, Dinan TG, Waddington JL
Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene × environment interaction.
Brain Behav Immun. 2012;26:660-671.     PMID: 22426432     (May 2012)

O'Tuathaigh CM, Desbonnet L, Moran PM, Waddington JL
Susceptibility genes for schizophrenia: mutant models, endophenotypes and psychobiology.
Curr Top Behav Neurosci. 2012; 12: 209-50.     PMID: 22367925     (May 2012)

Behan AT, Hryniewiecka M, O’Tuathaigh CMP, Kinsella A, Cannon M, Karayiorgou M, Gogos JA, Waddington JL, Cotter DR
Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways.
Neuropsychopharmacol. 2012;37(7):1773-83     PMID: 22434221     (May 2012)

O'Tuathaigh CMP, Desbonnet L, Lee P, Waddington JL
Catechol-O-methyltransferase as a drug target for schizophrenia.
CNS & Neurol Disord Drug Targets. 2012;11(3), 282-91.     PMID: 22483298     (May 2012)

Desbonnet L, Tighe O, Tarayiorgou M, Gogos JA, Waddington JL, O'Tuathaigh CM
Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice.
Behav Brain Res. 2012;228(2):351-8.     PMID: 22192380     (Mar 2012)

Walsh J, Desbonnet L, Clarke N, Waddington JL, O'Tuathaigh CMP.
Disruption of exploratory and habituation behavior in mice with mutation of DISC1: an ethologically based analysis.
J Neurocsi Res. 2012;90(7):1445-53.     PMID: 22388794     (Dec 2011)

Runker AE, O'Tuathaigh CM, Dunleavy M, Morris DW, Little GE, Corvin AP, Gill M, Henshall DC, Waddington JL, Mitchell KJ.
Mutation of semaphorin-6A disrupts limbic and cortical connectivity and models neurodevelopmental psychopathology.
PLoS One 6:26488, 2011.     PMID: 22132072     (Nov 2011)

Kas MJ, Kahn RS, Collier DA, Waddington JL, Ekelund J, Porteous DJ, Schughart K, & Hovatta I.
Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man.
Science Transl Med. 2011;3:102mr3.     PMID: 21957171     (Sep 2011)

Waddington JL, Hennessy, RJ, O'Tuathaigh CMP, Owoeye O, & Russell V.
Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redue.
In: The Origins of Schizophrenia (A.S. Brown & P.H. Harrison Eds), Columbia University Press, New York). 2012; pp 3 - 12.     PMID: doi:10.1017/S1461145711001581     (Sep 2011)

Tomiyama K, O’Tuathaigh CMP, Waddington JL.
Regulation of orofacial movement: amino acid mechanisms and mutant models.
Int Rev Neurobiol. 2011;97:61-75.     PMID: 21708307     (Sep 2011)

Waddington JL, O’Sullivan GJ, Tomiyama K.
Regulation of orofacial movement: dopamine receptor mechanisms and mutant models
Int Rev Neurobiol. 2011;97:39-60.     PMID: 21708306     (Sep 2011)

O'Tuathaigh CM, Desbonnet L. Moran PM, Kirby BP, Waddington JL.
Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges.
Curr Top Behav Neurosci. 2011;7:87-119.     PMID: 21298380     (Jun 2011)

Gangarossa G, Di Benedetto M, O'Sullivan GJ, Dunleavy M, Alcacer C, Bonito-Oliva A, Henshall DC, Waddington Jl, Valjent E, Fisone G.
Convulsant doses of a dopamine d1 receptor agonist result in erk-dependent increases in zif268 and aarc/arg3.1 expression in mouse dentate gyrus.
PLoS One 6:e19415.     PMID: 21559295     (May 2011)

Waddington JL, O’Tuathaigh CM, & Remington GJ.
The pharmacology and neuroscience of antipsychotic drugs.
In: Schizophrenia, Third Edition (D.R. Weinberger & P.J. Harrison, Eds), Wiley-Blackwell, Oxford. 2010; pp. 485-514.     PMID: DOI: 10.1002/9781444327298     (Mar 2011)

Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Gervin M, Kinsella A, Waddington JL, larkin C, O'Callaghan E.
The relationship between insight and neurological dysfunction in first-episode psychosis.
Eur Psychiatry. 2012; 27, 200-205.     PMID: 21392944     (Mar 2011)

Tomiyama K, Kim HA, Kinsella A, Ehrlich ME, Schutz G, Koshikawa N, Lawrence AJ, Waddington JL, Drago J.
Phenotypic disruption to orofacial movement topography in conditional mutants with generalised CamKlla/Cre D1Tox versus striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells.
Synapse 2011;65:835-42.     PMID: 21308794     (Jan 2011)

O'Tuathaigh CM, Hryniewiecka M, Behan A, Tighe O, Coughlan C, Desbonnet L, Cannon M, Karayiorgou M, Gogos JA, Cotter DR, Waddington JL.
Chronic adolescent exposure to ∆-9-tetrahydrocannabinol in COMT mutant mice:impact on psychosis-related and other phenotypes.
Neuropsychopharmacol. 2010;35:2262-73.     PMID: 20631688     (Oct 2010)

Kirby BP, Waddington JL, O'Tuathaigh CM.
Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption.
Brain Res Bull. 2010;83(3-4):162-76.     PMID: 19800398     (Sep 2010)

Raychaudhuri S, Korn JM, McCarroll SA; International Schizophrenia Consortium [including Waddington JL], Altshuler D, Sklar P, Purcell S, Daly MJ.
Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function.
PLoS Genet. 2010;6(9). pii: e1001097.     PMID: 20838587     (Sep 2010)

Cummings E, Donohoe G, McDonald C, Dinan TG, O'Neill FA, O'Callaghan E, Waddington JL, Murphy KC, Gill M, Morris DW, Corvin A
Clinical symptomatology and the psychosis risk gene ZNF804A.
Schizophr Res. 2010;122(1-3):273-5.     PMID: 20538430.     (Sep 2010)

Hennessy RJ, Baldwin PA, Browne DJ, Kinsella A, Waddington JL.
Frontonasal dysmorphlogy in bipolar disorder by 3D laser surface imaging and geometric morphometrics: comparisons with schizophrenia.
Schizophr Res. 2010;122:63-71.     PMID: 20554158     (Sep 2010)

Walsh J, Tighe O, Lai D, Harvey R, Karayiorgou M, Gogos JA, Waddington JL, O'Tuathaigh CM.
Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1.
Brain Res. 2012;1348:114-9.     PMID: 20561508     (Aug 2010)

Fujita S, Kiguchi M, Kobayashi M, Kinsella A, Koshikawa N. & Waddington JL.
Assessment of jaw movements by magnetic sensor in relation to topographies of orofacial behaviour in freely moving rats: Studies with the dopamine D(1)-like receptor agonists SKF 83822 vs SKF 83959.
Eur J Pharmacol. 2010;632(1-3):39-44.     PMID: 20122923     (Apr 2010)

O'Tuathaigh CM, Kirby BP, Moran PM. & Waddington JL.
Mutant Mouse Models: Genotype-phenotype relationships to negative symptoms in schizophrenia.
Schizophr Bull. 2010;36:271-88.     PMID: 19934211     (Mar 2010)

Fujita S, Kiguchi M, Kobayashi M, Koshikawa N, Waddington JL.
Involvement of NMDA receptors in the ventrolateral striatum of rats in apomorphine-induced jaw movements.
Brain Research 2010;1322:30-7.     PMID: 220122906     (Mar 2010)

Tomiyama K, Song L, Kobayashi M, Kinsella A, Kanematsu T, Hirata M, Koshikawa N, Waddington JL.
Orofacial movements in phospholipase C-related catalytically inactive protein (PRIP)-1/2 double knockout mice: effect of the GABAergic agent diazepam and the D(1) dopamine receptor agonist SKF 83959.
Synapse 2010;64:714-20.     PMID: 20340178     (Mar 2010)

Waddington JL, O’Tuathaigh CM. & Remington GJ
Second-generation antipsychotic drugs: mechanistically distinct or minor variants?
In: Therapeutic Strategies in Schizophrenia (A. Mortimer, & P. McKenna, Eds), Clinical Publishing, Oxford, pp 207-216, 2011.     PMID: n/a     (Mar 2010)

Omer S, Behan C, Waddington JL, O’Callaghan E.
Early intervention in pssychosis: service models worldwide and the Irish experience.
Ir J Psychol Med. 2010;27(4):210-214.     PMID: n/a     (Feb 2010)

Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Kinsella A, Waddington JL, Larkin C, O’Callaghan E.
Nonadherence to medication four years after a first episode of psychosis and associated risk factors.
Psychiatr Serv. 2010; 61(2):189-92.     PMID: 20123826     (Feb 2010)

O’Tuathaigh, CM, Waddington JL.
Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia. .
Schizophr Bull. 2010;36:243-5. Epub 2010 Feb 12.     PMID: 20154202     (Feb 2010)

Kelly BD, O'Callaghan E, Waddington JL, Feeney L, Browne S, Scully PJ, Clarke M, Quinn JF, McTigue O, Morgan MG, Kinsella A, Larkin C.
Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in Ireland.
Schizophr Res. 2010;116(1):75-89.     PMID: 19897342     (Jan 2010)

Roche E, Clarke M, Browne S, Turner N, McTuige O, Kamali M, Kinsellia A, Larkin C, Waddington JL, & O’Callaghan, E.
Prevalence and clinical correlates of depression in the acute phase of first episode schizophrenia.
Ir J Psych Med. 2010; 27, 15-18.     PMID: n/a     (Jan 2010)

Babovic D, Jiang L, Gantois I, Lawrence AJ, Ferreri V, Schutz G, Waddington JL. & Drago J.
Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells.
Behav Brain Res. 2010;206:78-87.     PMID: 19733597     (Jan 2010)

O’Sullivan GJ, O’Tuathaigh CM, Tomiyama K, Koshikawa, A. & Waddington JL.
Dopamine receptors and behavior: from psychopharmacology to mutant models.
In: The Dopamine Receptors (K. Neve, Ed), Humana Press, Totawa, NJ,     PMID: pp 323-371, 2010.     (Jan 2010)

O'Tuathaigh CM, Harte M, O'Leary C, O'Sullivan GJ, Blau C, Lai D, Harvey RP, Tighe O, Fagan AJ, Kerskens C, Reynolds GP, Waddington JL.
Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice.
Eur J Neurosci. 2010;31(2):349-58.     PMID: 20074216     (Jan 2010)

Desbonnet L, Waddington JL. & O’Tuathaigh CM.
Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?
Behav Brain Res. 2009;204(2):258-73.     PMID: 19728400     (Dec 2009)

Desbonnet L, Tomiyama K, Koshikawa N, O’Tuathaigh CM. & Waddington JL
Mutant and transgenic tools in modelling schizophrenia. In: Transgenic and Mutant Tools to Model Brain Disorders (A.V. Kalueff, Ed), Humana Press, Totawa, NJ
pp 217-239, 2010.     PMID: DOI: 10.1007/978-1-60761-474-6_12     (Nov 2009)

Turner, N., Browne, S., Clarke, M., Gervin, M., Larkin, C., Waddington, J.L. & O’Callaghan, E.
Employment status among those with psychosis at first presentation.
Soc Psychiat Psychiatric Epidemiol. 2009;44(10):863-9.     PMID: 19255700     (Oct 2009)

Bay-Richter C, O'Tuathaigh CM, O'Sullivan G, Heery DM, Waddington JL, Moran PM.
Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.
Int J Neuropsychopharmacol. 2009;12:403-14.     PMID: 19012810     (Apr 2009)

Tomiyama K, O’Tuathaigh CM, O’Sullivan GJ, Kinsella A, Lai D, Harvey RP, Tighe O, Croke DT, Koshikawa, N. & Waddington JL.
Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 ‘knockout’mice. Prog. Neuropsychopharmacol.
Biol Psychiatry. 2009;33(2):330-3.     PMID: 19150478     (Mar 2009)

Whitty PF, Owoeye O. & Waddington JL.
Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.
Schizophr. Bull. 2009;35(2):415-24.     PMID: 18791074     (Mar 2009)

Desbonnet L, Waddington JL. & O’Tuathaigh CM.
Mutant models for genes associated with schizophrenia.
Biochem. Soc. Trans. 2009;37(Pt 1):308-12.     PMID: 19143653     (Feb 2009)

Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, McTigue O, Kinsella A, Waddington JL, Larkin C. & O’Callaghan, E.
Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis.
Br. J. Psychiatry, 2009;194(1):18-24.     PMID: 19118320     (Jan 2009)

O’Tuathaigh CM, Desbonnet L. & Waddington JL.
Neuregulin-1 signaling in schizophrenia: ‘Jack of all trades’ or master of some ?
Expert Rev Neurother. 2009;9(1):1-3.     PMID: 19102663     (Jan 2009)

Owoeye O, Kingston T, Hennessy RJ, Baldwin PA, Browne D, Scully PJ, Kinsella A, Russell V, O’Callaghan E. & Waddington JL
The ‘totality’ of psychosis: epidemiology and developmental pathobiology. In: Search for the Causes of Schizophrenia (W.F. Gattaz & G. Busatto, Eds), Springer, New York
2010; pp 377-385.     PMID: DOI: 10.1007/978-1-4419-0913-8_21     (Jan 2009)

International Schizophrenia Consortium [including Waddington JL].
Rare chromosomal deletions and duplications increase risk of schizophrenia.
Nature. 2008;455(7210):237-41. Epub 2008 Jul 30.     PMID: 18668038     (Sep 2008)

Babovic D, O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Tighe O, Croke DT, Karayiorgou M, Gogos JA, Cotter D, Waddington JL
Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase.
Neuroscience. 2008;155(4):1021-9.     PMID: 18674597     (Sep 2008)

Yang MS, Morris DW, Donohoe G, Kenny E, O'Dushalaine CT, Schwaiger S, Nangle JM, Clarke S, Scully P, Quinn J, Meagher D, Baldwin P, Crumlish N, O'Callaghan E, Waddington JL, Gill M, Corvin A.
Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism.
Biol Psychiatry. 2008;64(2):98-103.     PMID: 18281018     (Jul 2008)

O'Sullivan GJ, Dunleavy M, Hakansson K, Clementi M, Kinsella A, Croke DT, Drago J, Fienberg AA, Greengard P, Sibley DR, Fisone G, Henshall DC, Waddington JL
Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.
Neuropharmacology. 2008;54(7):1051-61.     PMID: 18367215     (Jun 2008)

Waddington JL, Brown AS, Lane A, Schaefer CA, Goetz RR, Bresnahan M, Susser ES.
Congenital anomalies and early functional impairments in a prospective birth cohort: risk of schizophrenia-spectrum disorder in adulthood.
Br J Psychiatry. 2008;192(4):264-7.     PMID: 18378985     (Apr 2008)

Jackson D, Lawoyin R, Gaynor K, Clarke M, Browne S, Renwick L, Sutton M, Turner N, Kinsella A, Waddington JL, Larkin C, Callaghan EO.
Is the duration of untreated psychosis temporally stable?
Eur Psychiatry. 2008;23(2):97-9.     PMID: 17945469     (Mar 2008)

O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Lai D, Harvey R, Croke DT, Waddington JL.
Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1.
Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):462-6.     PMID: 17980471     (Feb 2008)

Morris DW, Murphy K, Kenny N, Purcell SM, McGhee KA, Schwaiger S, Nangle JM, Donohoe G, Clarke S, Scully P, Quinn J, Meagher D, Baldwin P, Crumlish N, O'Callaghan E, Waddington JL, Gill M, Corvin AP.
Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility.
Biol Psychiatry. 2008;63(1):24-31.     PMID: 17618940     (Jan 2008)

Babovic D, O'Tuathaigh CM, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT, Karayiorgou M, Gogos JA, Cotter D, Waddington JL.
Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice.
Behav Brain Res. 2007;183:236-9.     PMID: 17707921     (Nov 2007)

Corvin A, McGhee KA, Murphy K, Donohoe G, Nangle JM, Schwaiger S, Kenny N, Clarke S, Meagher D, Quinn J, Scully P, Baldwin P, Browne D, Walsh C, Waddington JL, Morris DW, Gill M.
Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample.
Am J Med Genet B Neuropsychiatr Genet. 2007;144B(7):949-53.     PMID: 17492767     (Oct 2007)

Teper Y, Whyte D, Cahir E, Lester HA, Grady SR, Marks MJ, Cohen BN, Fonck C, McClure-Begley T, McIntosh JM, Labarca C, Lawrence A, Chen F, Gantois I, Davies PJ, Petrou S, Murphy M, Waddington J, Horne MK, Berkovic SF, Drago J.
Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation.
J Neurosci. 2007;27(38):10128-42.     PMID: 17881519     (Sep 2007)

Aono Y, Saigusa T, Watanabe S, Iwakami T, Mizoguchi N, Ikeda H, Ishige K, Tomiyama K, Oi Y, Ueda K, Rausch WD, Waddington JL, Ito Y, Koshikawa N, Cools AR.
Role of alpha adrenoceptors in the nucleus accumbens in the control of accumbal noradrenaline efflux: a microdialysis study with freely moving rats.
J Neural Transm. 2007;114(9):1135-42.     PMID: 17533511     (Sep 2007)

Waddington JL, Corvin AP, Donohoe G, O'Tuathaigh CM, Mitchell KJ, Gill M.
Functional genomics and schizophrenia: endophenotypes and mutant models.
Psychiatr Clin North Am. 2007;30(3):365-99. Review.     PMID: 17720028     (Sep 2007)

Waddington JL.
Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome.
Br J Psychiatry Suppl. 2007;50:s52-7. Review.     PMID: 18019045     (Aug 2007)

O'Tuathaigh CM, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT, Harvey R, Waddington JL.
Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1.
Neuroscience. 2007;147(1):18-27.     PMID: 17512671     (Jun 2007)

Ishige K, Takagi N, Imai T, Rausch WD, Kosuge Y, Kihara T, Kusama-Eguchi K, Ikeda H, Cools AR, Waddington JL, Koshikawa N, Ito Y.
Role of caspase-12 in amyloid beta-peptide-induced toxicity in organotypic hippocampal slices cultured for long periods.
J Pharmacol Sci. 2007;104(1):46-55.     PMID: 17452809     (May 2007)

Hennessy RJ, Baldwin PA, Browne DJ, Kinsella A, Waddington JL.
Three-dimensional laser surface imaging and geometric morphometrics resolve frontonasal dysmorphology in schizophrenia.
Biol Psychiatry. 2007;61(10):1187-94.     PMID: 17217929     (May 2007)

Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, Teper Y, Jupp B, Ziebell J, Morganti-Kossmann CM, O'Brien TJ, Nally R, Schutz G, Waddington J, Egan GF, Drago J.
Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior.
Proc Natl Acad Sci U S A. 2007;104(10):4182-7.     PMID: 17360497     (Mar 2007)

Makihara Y, Okuda Y, Kawada C, Matsumoto M, Waddington JL, Koshikawa N, Tomiyama K.
Differential involvement of cyclase- versus non-cyclase-coupled D1-like dopamine receptors in orofacial movement topography in mice: studies with SKF 83822.
Neurosci Lett. 2007;415(1):6-10.     PMID: 17234342     (Mar 2007)

O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL.
Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour.
Neurosci Biobehav Rev. 2007;31(1):60-78.     PMID: 16782199     (Jan 2007)

Clarke M, Whitty P, Browne S, Mc Tigue O, Kinsella A, Waddington JL, Larkin C, O'Callaghan E
Suicidality in first episode psychosis.
Schizophr Res. 2006;86(1-3):221-5.     PMID: 16846719     (Sep 2006)

Clarke M, Whitty P, Browne S, McTigue O, Kamali M, Gervin M, Kinsella A, Waddington JL, Larkin C, O'Callaghan E
Untreated illness and outcome of psychosis.
Br J Psychiatry. 2006;189:235-40.     PMID: 16946358     (Sep 2006)

Tomiyama K, Makihara Y, Yamamoto H, O'Sullivan G, Nally RE, Tighe O, Kinsella A, Fienberg AA, Grandy DK, Sibley DR, Croke DT, Koshikawa N, Waddington JL.
Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'.
Eur Neuropsychopharmacol. 2006;16(6):437-45     PMID: 16413758     (Aug 2006)

Fujita S, Lee J, Kiguchi M, Uchida T, Cools AR, Waddington JL, Koshikawa N.
Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Eur J Pharmacol. 2006;538(1-3):94-100.     PMID: 16682023     (May 2006)

O'Sullivan GJ, Kinsella A, Grandy DK, Tighe O, Croke DT, Waddington JL.
Ethological resolution of behavioral topography and D2-like vs. D1-like agonist responses in congenic D4 dopamine receptor "knockouts": identification of D4:D1-like interactions.
Synapse. 2006;59(2):107-18.     PMID: 16320306     (Feb 2006)

Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, Williams HJ, Preece AC, Dwyer S, Wilkinson JC, Spurlock G, Kirov G, Buckland P, Waddington JL, Gill M, Corvin AP, Owen MJ, O'Donovan MC.
Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia.
Am J Med Genet B Neuropsychiatr Genet. 2006;141B(1):96-101.     PMID: 16249994     (Jan 2006)

Hennessy RJ, McLearie S, Kinsella A, Waddington JL.
Facial shape and asymmetry by three-dimensional laser surface scanning covary with cognition in a sexually dimorphic manner.
J Neuropsychiatry Clin Neurosci. 2006;18(1):73-80.     PMID: 16525073     (Jan 2006)

O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, Harvey RP, Tighe O, Croke DT, Waddington JL.
Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice.
Neuroreport. 2006;17(1):79-83     PMID: 16361955     (Jan 2006)

Parish CL, Nunan J, Finkelstein DI, McNamara FN, Wong JY, Waddington JL, Brown RM, Lawrence AJ, Horne MK, Drago J.
Mice lacking the alpha4 nicotinic receptor subunit fail to modulate dopaminergic neuronal arbors and possess impaired dopamine transporter function.
Mol Pharmacol. 2005 Nov;68(5):1376-86.     PMID: 16077034     (Nov 2005)

Parish CL, Nunan J, Finkelstein DI, McNamara FN, Wong JY, Waddington JL, Brown RM, Lawrence AJ, Horne MK, Drago J.
Mice lacking the alpha4 nicotinic receptor subunit fail to modulate dopaminergic neuronal arbors and possess impaired dopamine transporter function.
Mol Pharmacol. 2005 Nov;68(5):1376-86.     PMID: 16077034     (Nov 2005)

Waddington JL, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, Croke DT.
Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.
Psychopharmacology (Berl). 2005 Oct;181(4):611-38.     PMID: 16041535     (Oct 2005)

Hennessy RJ, McLearie S, Kinsella A, Waddington JL.
Facial surface analysis by 3D laser scanning and geometric morphometrics in relation to sexual dimorphism in cerebral--craniofacial morphogenesis and cognitive function.
J Anat. 2005 Sep;207(3):283-95.     PMID: 16185253     (Sep 2005)

McGhee KA, Morris DW, Schwaiger S, Nangle JM, Donohoe G, Clarke S, Meagher D, Quinn J, Scully P, Waddington JL, Gill M, Corvin A.
Investigation of the apolipoprotein-L (APOL) gene family and schizophrenia using a novel DNA pooling strategy for public database SNPs.
Schizophr Res. 2005 Jul;76(2-3):231-8.     PMID: 15949655     (Jul 2005)

Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, Owens JM, Russell V, O'Callaghan E, Waddington JL.
Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years.
Schizophr Bull. 2005 Jul;31(3):624-38.     PMID: 15944446     (Jul 2005)

O'Sullivan GJ, Kinsella A, Sibley DR, Tighe O, Croke DT, Waddington JL.
Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions.
Synapse. 2005 Mar 15;55(4):201-11.     PMID: 15668951     (Mar 2005)

Makihara Y, Yamamoto H, Inoue M, Tomiyama K, Koshikawa N, Waddington JL.
Topographical effects of D1-like dopamine receptor agonists on orofacial movements in mice and their differential regulation via oppositional versus synergistic D1-like: D2-like interactions: cautionary observations on SK&F 82958 as an anomalous agent.
J Psychopharmacol. 2004 Dec;18(4):484-95.     PMID: 15585467     (Dec 2004)

Nally RE, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, Waddington JL.
Ethologically based resolution of D2-like dopamine receptor agonist-versus antagonist-induced behavioral topography in dopamine- and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kDa "knockout" mutants congenic on the C57BL/6 genetic background.
J Pharmacol Exp Ther. 2004 Sep;310(3):1281-7.     PMID: 15140917     (Sep 2004)

O'Sullivan GJ, Clifford JJ, Tomiyama K, Koshikawa N, Drago J, Sibley DR, Croke DT, Waddington JL.
D1-like dopamine receptor-mediated function in congenic mutants with D1 vs. D5 receptor "knockout".
J Recept Signal Transduct Res. 2004 Aug;24(3):107-16.     PMID: 15521357     (Aug 2004)

Meagher DJ, Quinn JF, Bourke S, Linehan S, Murphy P, Kinsella A, Mullaney J, Waddington JL.
Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population.
Psychiatry Res. 2004 May 30;126(3):217-27.     PMID: 15157748     (May 2004)

Williams NM, Preece A, Morris DW, Spurlock G, Bray NJ, Stephens M, Norton N, Williams H, Clement M, Dwyer S, Curran C, Wilkinson J, Moskvina V, Waddington JL, Gill M, Corvin AP, Zammit S, Kirov G, Owen MJ, O'Donovan MC.
Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1).
Arch Gen Psychiatry. 2004 Apr;61(4):336-44.     PMID: 15066891     (Apr 2004)

Hennessy RJ, Lane A, Kinsella A, Larkin C, O'Callaghan E, Waddington JL.
3D morphometrics of craniofacial dysmorphology reveals sex-specific asymmetries in schizophrenia.
Schizophr Res. 2004 Apr 1;67(2-3):261-8.     PMID: 14984886     (Apr 2004)

Scully PJ, Owens JM, Kinsella A, Waddington JL.
Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate.
Schizophr Res. 2004 Apr 1;67(2-3):143-55.     PMID: 14984873     (Apr 2004)

O'Sullivan GJ, Roth BL, Kinsella A, Waddington JL.
SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
Eur J Pharmacol. 2004 Feb 23;486(3):273-80.     PMID: 14985049     (Feb 2004)

Waddington JL, Scully PJ, Quinn JF, Meagher DJ, Morgan MG
The origin and course of schizophrenia: implications for clinical practice.
J Psychiatr Pract. 2001 Jul;7(4):247-52.     PMID: 15990531     (Jul 2001)

Book Chapters

Kobayashi M, Koshikawa N, Iwata K, & Waddington JL. (eds)
Translating Mechanisms of Orofacial Neurological Disorder.
Academic Press, San Diego, pp. 1-381.     (Sep 2011)

Buckley, P.F. & Waddington, J.L. (Eds).
Schizophrenia and Mood Disorders: the New Drug Therapies in Clinical Practice.
Butterworth Heinemann, Oxford, pp. 1-353, 2000.     (Jan 2000)

Waddington, J.L. & Buckley, P.F. (Eds.)
The Neurodevelopmental Basis of Schizophrenia.
Chapman & Hall, New York, pp. 1-186, 1996.     (Jan 1996)

Waddington, J.L. (Ed.)
D-1:D-2 Dopamine Receptor Interactions: Neuroscience and Psychopharmacology.
Academic Press, London, pp. 1-296, 1993.     (Jan 1993)

Joseph, M.H. & Waddington, J.L. (Eds.)
Working Methods in Neuropsychopharmacology.
Manchester University Press, Manchester, pp. 1-232, 1986.     (Jan 1986)

O'Malley, K. & Waddington, J.L. (Eds.)
Therapeutics in the Elderly: Scientific Foundations and Clinical Practice.
Elsevier, Amsterdam, pp. 1-223, 1985.     (Jan 1985)

Theses

Student Name: Claire O'Leary (PhD / 4 yrs)
Thesis Title: Phenotypic characterisation of mice mutant for genes associated with psychosis
Awarding Institution:  

Student Name: Emilie Petit (PhD / 3 yrs)
Thesis Title: Phenotypic characterisation of mice mutant for genes associated with psychosis
Awarding Institution:  

Bio-Photonics Imaging Platform

Category of your Research: Imaging

Sub-category: Small Animal, Human

Title of Project: 3D Surface Imaging and Geometric Morphometrics to Study Dysmorphology as an Index of Dysmorphogensis and its biometric applications.

Description of your Research Project:

Our work in the neuroscience programme, RCSI, involves the development and application of technologies [hardware and software] for (a) accessing the developmental biology of the central nervous system and measuring disruption to these processes in patients with neuropsychiatric disorders of early developmental origin and (b) the application of these technologies to mutant and other animal models of such disorders. Because of the embryological unity with which the brain and face develop over early fetal life, disruption to brain development over this period is reflected in disruption to craniofacial development. Furthermore, as development is an intrinsically 3-dimensional process, accessing craniofacial dysmorphogenesis in terms of 3D shape analysis of dysmorphology is fundamental to this approach. We are pioneering the application of 3D laser surface imaging and geometric morphometric analysis of 3D facial shape parameters in relation to (a) indices of brain function in normal subjects, (b) clarifying the early developmental origin of neuropsychiatric disorders and (c) initial studies of animal models thereof.

Scientific challenges that will be addressed and solved within the Platform, in close collaboration with colleagues in DCU and our network of inter-institutional, national, international and industrial collaborators, include: (a) development and application of geometric morphometric algorithms to the analysis and ‘dynamic’ visualisation of 3D facial shape as captured by 3D laser surface imaging in human subjects; (b) acquisition and analysis of similar data from 3D fetal ultrasound; (c) acquisition and analysis of similar 3D facial surface data from MR imaging in human subjects; and (d) the acquisition and analysis of similar data from MR imaging in rodents and non-human primates. In particular, the Platform will provide a basis for applying novel imaging technologies to critical scientific questions, and for the further development and application of associated analytical and visualization techniques for 3D laser surface, ultrasound and both clinical and small-bore 7T animal MR imaging data.

These studies will deliver novel techniques for enhanced geometric morphometric analysis and visualisation of resultant 3D statistical models for data from a variety of imaging modalities: laser surface imaging; MRI; ultrasound. They will be applied to a variety of critical clinical challenges. In particular, they will provide important new insights into mechanisms of dysmorphogenesis in psychotic illness, especially schizophrenia and bipolar disorder.

These studies will deliver novel techniques for acquiring and analysing 3D facial and brain images in mice using 7T small-bore MRI. They will apply the enhanced geometric morphometric analysis and visualisation of resultant 3D statistical models described above to a variety of critical preclinical challenges. In particular, they will provide important new insights into processes of dysmorphogenesis in mice mutant for genes associated with increased risk for schizophrenia, together with analysis of non-human primate MR imaging studies.

These studies will deliver novel techniques for matching a given subject to a search gallery using 3D facial shape analysis. They will be applied to a variety of critical analytical and commercial challenges in the domain of biometrics/security and e-business. In particular, they will provide important new approaches to match-search algorithms on the basis of 3D as opposed to 2D data.


 

Training Initiatives

RCSI 4-year MRes/PhD programme.
Participated fully since inception in the development and delivery of the programme. As the first such programme in Ireland, it has served as the progenitor for similar programmes in other institutions.  (2001) 

National Science Week
Delivered a public lecture in Tralee on the neuroscience of brain imaging.  (2001) 

National Science Week
Organized a public meeting in Dublin on the neuroscience of Alzheimer’s disease and multiple sclerosis, chaired by Pat Kenny.  (2002) 

Funding Awards

Funding Agency: Enterprise Ireland
€18398 [RCSI], €0 [Other], ()
Assistive Technologies in Autism and Intellectual Disability (ASSISTID)
Lead Applicant : Prof Brian Harvey
RCSI Co-applicants: John Waddington
Non RCSI Co-applicants: Geraldine Leader - NUIG, Lizbeth Goodman - UCD, Liam Walsh - RESPECT, John Drismore - TCD, Michael Leahy - MSU, Wiiliam McIlvane - Univ Massacheutas, Nancy Salmon - UL, Paul Whelan - DCU

Funding Agency: SFI
€1446222 [RCSI], €0 [Other], (Oct 2012)
Targeted disruption of genes related to neuropsychiatric disease and translational phenotypes
Lead Applicant : Prof John Waddington

Funding Agency: SFI
€5600 [RCSI], €0 [Other], (May 2008)
Examination of cognitive function in a genetic model of schizophrenia: focus on neuregulin-1
Lead Applicant : Prof John Waddington
RCSI Co-applicants: John Waddington

Funding Agency: IRCSET - Embark post-doctoral fellowship (Kerstin Hakansson)
€96,300 [RCSI], €0 [Other], (Apr 2007)
Studies on the mechanism of action of neuroleptic drugs: identification of specific molecular components involved in the generation of tardive dyskinesia
Lead Applicant : Prof John Waddington

Funding Agency: Wellcome Trust
€184,212 [RCSI], €0 [Other], (Sep 2005)
Resource for Psychiatric Genomics Ireland
Lead Applicant : Prof John Waddington

Funding Agency: SFI - Supplement award (equipment)
€309,170 [RCSI], €0 [Other], (May 2005)
Targeted gene deletion of dopamine receptor subtypes and associated transduction mechanisms: systematic comparison of functional phenotype and platforms for drug discovery in congenic ‘knockouts’”
Lead Applicant : Prof John Waddington

Funding Agency: HRB - Equipment grant
€65,384 [RCSI], €0 [Other], (Dec 2004)
Resource for Psychiatric Genomics in Ireland: accessing disruption to early brain development and quantifying it's relationship to functional impairment through morphometrics
Lead Applicant : Prof John Waddington

Funding Agency: Enterprise Ireland
€6,887 [RCSI], €[Other], (Nov 2004)
Phenotypic characterisation of an automnal dominan
Lead Applicant : Prof John Waddington

Funding Agency: Various sources (incl Stanley Foundation)
€44,712 [RCSI], €0 [Other], (Apr 2004)
Neurosurgery
Lead Applicant : Prof John Waddington

Funding Agency: SFI
€963,814 [RCSI], €0 [Other], (Dec 2003)
Targeted Gene Deletion of Dopamine Receptor Subtypes and Associated Transduction Mechanisms: Systematic Comparison of Functional Phenotype and Platforms for Drug Discovery in Congenic ‘Knockouts’”
Lead Applicant : Prof John Waddington

Funding Agency: HRB
€??? [RCSI], €0 [Other], (Jun 2003)
Roles of D1a,D2 & D3
Lead Applicant : Prof John Waddington

Funding Agency: HEA - PRTLI 2
€64,154 [RCSI], €0 [Other], (Jul 2001)
Drug targeting
Lead Applicant : Prof John Waddington

Funding Agency: Enterprise Ireland
€80,570 [RCSI], €0 [Other], (Sep 2000)
Comparative phenotypes following targeted gene deletion of the D1A dopamine receptor and DARPP-32.
Lead Applicant : Prof John Waddington

Funding Agency: Gaelen
€33,159 [RCSI], €0 [Other], (Sep 2000)
Knockouts & transgenics
Lead Applicant : Prof John Waddington

Funding Agency: HEA - PRTLI cycle 1
€236,045 [RCSI], €0 [Other], (Feb 2000)
Drug targeting
Lead Applicant : Prof John Waddington

Funding Agency: RCSI
€33,159 [RCSI], €0 [Other], (Sep 1999)
Congenic DIA & D3
Lead Applicant : Prof John Waddington

Funding Agency: Various funding sources
€140,873 [RCSI], €0 [Other], (May 1998)
Schizophenia/bipolar
Lead Applicant : Prof John Waddington

Funding Agency: Stanley Foundation
€1,303,978 [RCSI], €0 [Other], (Mar 1994)
Schizophenia/bipolar
Lead Applicant : Prof John Waddington

Funding Agency: Various funding sources
€118,509 [RCSI], €0 [Other], (Mar 1994)
Schizophenis
Lead Applicant : Prof John Waddington